CU6.AX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (20 geg. 2024 @ 03:38):

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults...

Stats
Dzisiejszy wolumen	183 582
Średni wolumen	813 048
Kapitalizacja rynkowa	1.15B
EPS	$0 ( 2023-08-24 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-35.25
ATR14	$0.0160 (0.38%)

Wolumen Korelacja

Długi: 0.09 (neutral)

Krótki: 0.42 (neutral)

Signal:(69.232) Neutral

Clarity Pharmaceuticals Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Clarity Pharmaceuticals Korelacja - Waluta/Towar

-0.44
( neutral )

-0.42
( neutral )

0.00
( neutral )

0.54
( weak )

Clarity Pharmaceuticals Finanse

Annual	2023
Przychody:	$9.80M
Zysk brutto:	$9.70M (98.97 %)
EPS:	$-0.0945

FY	2023
Przychody:	$9.80M
Zysk brutto:	$9.70M (98.97 %)
EPS:	$-0.0945

FY	2022
Przychody:	$6.46M
Zysk brutto:	$6.41M (99.28 %)
EPS:	$-0.0956

Financial Reports:

No articles found.

Clarity Pharmaceuticals Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Clarity Pharmaceuticals

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.